Cancer Cause and Prevention Research
Active
- Assistance listing
- 93.393
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- 18,704 $20,360,631,536 in federal obligations
Program facts
- Assistance types
-
- Project Grant
- Cooperative Agreement
- Block Grant
- Treasury account
-
- 75-0849-0-1-550
- More information
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The National Institutes of Health National Cancer Institute funds cancer cause and prevention research through CFDA 93.393, with the most recent grant award dated September 3, 2026. This program identifies cancer risks and risk reduction strategies, supports discovery of cancer etiology and prevention mechanisms, and funds both traditional research grants and SBIR/STTR commercialization initiatives across eleven research domains including chemical carcinogenesis, screening and early detection, epidemiology, nutrition, immunology and vaccines, cancer chemoprevention, clinical trials, and quality of life outcomes. Research performed must occur in the U.S. and its possessions.
Over 18,700 grants totaling $20.36 billion in federal dollars obligated since 1976 demonstrate sustained program activity. In the past five years, annual award volume has ranged from 182 to 351 awards, with 208 awards in 2026 year-to-date. The program is dominated by the National Cancer Institute, which accounts for 4,041 awards ($12.51 billion), followed by the broader NIH ($14,215 awards; $7.07 billion) and HHS ($430 awards; $738.9 million). The award portfolio is predominantly Project Grants (86%), with smaller shares of Cooperative Agreements (10%) and Block Grants (4%). Recipients include universities, colleges, hospitals, nonprofits, and for-profit organizations; SBIR applicants must be domestic small businesses with no more than 500 employees and cannot be dominant in their field.
Representative recent awards reflect the breadth of funded activities. An R01 grant to study e-cigarette influencer marketing on social media and adolescent perceptions ($733,023) addresses cancer risk reduction. A Cooperative Agreement supporting the Non-Invasive Post-Polypectomy Surveillance Study ($671,426) develops and evaluates non-invasive strategies for colorectal cancer surveillance. An R01 grant investigating the role of epigenetic factors in leukemia therapeutics ($622,070) funds basic mechanistic research. Additional recent awards support digital health interventions for symptom management after CAR-T therapy ($201,112), pharmacist-led tobacco treatment in federally qualified health centers ($669,910), and novel sunscreen formulations with DNA repair capability ($400,000).
Several opportunities remain open or recently posted. PAR-28-037, the Parent R35 Investigator-Focused Award (posted July 30, 2026), supports research programs for investigators at all career stages with funding stability and scientific freedom. RFA-CA-28-003, Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (posted July 28, 2026), solicits U24 Cooperative Agreements to advance informatics tools and software. PAR-28-014, Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (posted March 10, 2026; due October 11, 2029), invites RP1 applications investigating sporadic non-hereditary early-onset cancers in persons aged 18 to 49. PAR-28-056 and PAR-28-057, the Pancreatic Cancer Detection Consortium Research Units and Management/Data Coordination Unit (posted February 11, 2026), support multi-disciplinary teams developing and validating biomarkers for early detection and risk stratification in pancreatic ductal adenocarcinoma.
Objective and description
- Objective
To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans. Research programs include: (1) chemical, phy
- Description
To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans. Research programs include: (1) chemical, physical and molecular carcinogenesis; (2) screening, early detection and risk assessment, including biomarker discovery, development and validation; (3) epidemiology; (4) nutrition and bioactive food components; (5) immunology and vaccines; (6) field studies and statistics; (7) cancer chemoprevention and interception; (8) pre-clinical and clinical agent development; (9) organ site studies and clinical trials; (10) health-related quality of life and patient-centered outcomes; and (11) supportive care and management of symptoms and toxicities. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to stimulate technical innovation; to increase private sector commercialization of innovations derived from Federal research and development funding; to increase small business participation in Federal research and development; and to foster and encourage participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer through cooperative research and development between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development funding, and foster participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons.
Eligibility
- Applicant eligibility
The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one- half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concern (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.
- Beneficiary eligibility
Any nonprofit or for-profit organization, company, or institution engaged in biomedical research on cancer.
- Uses of assistance
Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. Restrictions are imposed against the use of funds for entertainment, foreign travel (unless specifically authorized), office equipment, and other items not normally necessary for the effective prosecution of such research. SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. The SBIR Fast-Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization. Fast-Track is a parallel review option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.
- Length and time phasing of assistance
Grants and Cooperative Agreements: Average 3 to 4 years, maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funding is provided through Monthly Demand Payment System or Letter of Credit. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.
How to apply
- Criteria for selecting proposals
The major elements in evaluating proposals include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; 2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.
- Award procedure
Grant applications are evaluated by scientific authorities for scientific and technical merit. Applications must also be reviewed by the National Cancer Advisory Board. All competitive applications compete for available funds on the basis of scientific and technical merit, program relevance, and program balance, consistent with NCI and NIH priorities and strategic plans. Initial award provides funds for the first budget period (usually 12 months) and Notice of Grant Award (Form PHS 1533-2) indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.
- Time to approval or disapproval
(Grants) Approximately 10 months. SBIR/STTR: About 7-1/2 months.
- Renewals
Applications submitted for renewal must be reviewed and selected for funding on a competitive basis.
- Appeals
A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available online through the NIH home page at http://www.grants.nih.gov/grants/guide/notice-files/not97-232.html
Grant opportunities
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Grant awards
Latest 10 of 18,704 listed here. See the rest on GovTribe.
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | The Univeristy Of Texas M.d. Anderson Cancer Center | $459,263,998 | 2% |
| 2 | The Trustees Of Columbia University In The City Of New York | $356,555,437 | 2% |
| 3 | Dana-Farber Cancer Institute, Inc. | $347,629,130 | 2% |
| 4 | Mayo Clinic | $342,272,476 | 2% |
| 5 | University Of North Carolina At Chapel Hill | $329,301,775 | 2% |
| 6 | Sloan-Kettering Institute For Cancer Research | $318,108,665 | 2% |
| 7 | Vanderbilt University Medical Center | $303,449,789 | 1% |
| 8 | The Regents Of The University Of California. San Francisco | $301,157,727 | 1% |
| 9 | University Of Southern California | $300,488,112 | 1% |
| 10 | The Trustees Of The University Of Pennsylvania | $296,397,500 | 1% |
10 of 777 recipients listed here. See the rest on GovTribe.
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2026 | $727,696,547 |
| FY2025 | $1,421,006,015 |
| FY2024 | $1,551,610,254 |
| FY2023 | $1,718,579,026 |
| FY2022 | $1,598,270,484 |
| FY2021 | $1,380,383,037 |
| FY2020 | $703,931,059 |
| FY2019 | $694,327,663 |
| FY2018 | $667,213,298 |
| FY2017 | $666,983,648 |
| FY2016 | $652,922,074 |
| FY2015 | $668,460,292 |
| FY2014 | $667,802,193 |
| FY2013 | $695,421,190 |
| FY2012 | $760,605,505 |
| FY2011 | $748,116,897 |
| FY2010 | $732,679,525 |
| FY2009 | $689,856,886 |
| FY2008 | $345,364,514 |
| FY2007 | $445,240,481 |
| FY2006 | $676,336,073 |
| FY2005 | $716,675,134 |
| FY2004 | $714,213,000 |
| FY2003 | $633,767,021 |
| FY2002 | $587,606,973 |
| FY2001 | $256,453,079 |
Show all 26
Quick answers
What is Assistance Listing 93.393?
Assistance Listing 93.393 is Cancer Cause and Prevention Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for Cancer Cause and Prevention Research?
Its CFDA number is 93.393: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.393 awarded?
18,704 grant awards under 93.393 have obligated $20,360,631,536 in federal funds to 777 recipients.
Who receives the most funding from 93.393?
The recipients obligated the most under Cancer Cause and Prevention Research are The Univeristy Of Texas M.d. Anderson Cancer Center ($459,263,998), The Trustees Of Columbia University In The City Of New York ($356,555,437) and Dana-Farber Cancer Institute, Inc. ($347,629,130).
How much did 93.393 obligate in fiscal year 2025?
Grants under 93.393 obligated $1,421,006,015 in federal funds in fiscal year 2025.
Are there open grant opportunities under 93.393?
36 of the latest 50 opportunities under 93.393 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program